Abstract: Islet transplantation is a cellular replacement therapy to treat severe diabetes mellitus,
97
The liver has been used as a site for clinical islet transplantation for a long time. It is the largest 98 organ that can accommodate large numbers of islets following a simple transplant procedure
99
(percutaneous infusion into intrahepatic portal vein using ultrasonography under local anesthesia)
100
[34]. On the other hand, the liver also has some problems as a transplant site. Many islets are transplantation has lagged [50] . Muscle and subcutaneous tissues have also been examined as
126
candidate transplantation sites, as the transplantation procedure and biopsies can be performed
127
easily with minimal invasion and few complications. These sites suffer from hypovascularity and 128 hypoxia, and transplantation efficacy could be improved if these obstacles were overcome,
129
especially in subcutaneous tissue [26] . Another problem with these sites is systemic insulin release.
130
In general, secreted insulin from the pancreas flows into the liver via the portal vein, and therefore
131
smaller amounts of insulin are needed to control blood glucose. This is referred to as physiological privileged" sites. The "immune privilege" of these sites was once assumed to be due to lack of cellular infiltration and lymphatic drainage [59] , but more recently it has been shown that this is
153
provided by a complex of immune responses [60] . For example, the brain, testis and retina-blood 154 barrier are maintained in an immunosuppressed condition due to a cellular physical shield [60] [61] [62] .
155
In some cases, regulatory T cells (Tregs) also contribute to immune privilege. Larocque and
156
colleagues showed that the immune response in the brain could be normally activated when contribute to immune tolerance in the rodent anterior chamber when challenged by myelin antigen immune privileged sites in using non-human animals. While such studies in animals have demonstrated the effectiveness of transplantation into immune privileged sites [27, 28, 30, 32] , little has been done in a human clinical setting. In particular, the brain or eye are problematic sites for Among the candidate islet transplant sites, the spleen may come closest to being an ideal site.
167
The spleen is a highly vascularized organ which receives blood from the splenic artery and drains
168
into the portal venous system. Vascularization is the most important factor determining the success
169
of transplantation, and the spleen provides a rich oxygen and nutrition supply. Another advantage 170 is that islets transplanted into the spleen can achieve physiological levels of insulin secretion, as 171 insulin produced by pancreatic β cells flows into the portal -splenic vein (portal venous circulation)
172
[66]. In contrast, insulin provided by a subcutaneous pump or by injection is delivered directly into 173 systemic circulation. Recent advances in these insulin injection systems enable them to achieve close 174 to physiological insulin release profiles (i.e. in the portal system), but there is still a limitation in day-
175
to-day changes in insulin sensitivity [67] . As the spleen connects to the portal venous system, as does the liver and pancreas, insulin released from transplanted islets flows into the splenic vein.
177
The spleen is the site responsible for immune tolerance, and tends to be somewhat 
219
In summary, the spleen may be close to an optimal site for islet transplantation due to its rich 
227

Outcomes of Intrasplenic Islet Transplantation
229
The major studies on intrasplenic islet transplantation are summarized in (Table 3) .
259
Next, the route of transplantation into the spleen needs to be considered. In the earliest studies,
260
the pulp was used as the transplant site in the spleen [86, 88] 
271
To examine the potential usefulness of the spleen as an islet transplantation site and to try to 
313
In conclusion, the spleen has historically been an important site for islet transplantation, but its 314 utility could be greatly improved by the application of some recent novel findings and techniques.
315
We would advocate the development of clinical methods to optimize the safe and effective 316 transplantation of islets into the spleen.
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